Emcure Pharmaceuticals Limited · NSE:EMCURE
Emcure Pharmaceuticals — Q2 FY27 Earnings Presentation
12 slides from Emcure Pharmaceuticals's earnings presentation, Nov 3, 2026
Slide 1: Exchange intimation letter for results presentation
Emcure Ref: EPL/CS/SE/0095/2026 Date: November 03, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear
Slide 2: Q2FY27 Results Presentation
Complex Science. Disciplined Execution. Compounding Value. Q2FY27 Results Presentation 03 November 2026 24.3% 30.9% 29.3% Operating Revenue EBITDA growth PAT Growth (Q2FY27) Growth Q2FY27 (Q2FY27) ▲45 bps YoY ▲103 bps YoY 1
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about futur
Slide 4: Contents
Contents Page 4 Key Financial Highlights 4 5 Other Financial Data Points 5 6 Domestic Business Performance 6 7 International Business Performance 7 8 P&L Summary 8 9 Balance Sheet Summary 9 10 Cash Flow Summary 10 3
Slide 5: Q2FY27 - Key Financial Highlights
Q2FY27 - Key Financial Highlights REVENUE (INR Mn) Revenue Growth – Q2FY27 YoY Q2FY27 Revenue Mix 28,205 24.3% YoY Growth EBITDA (INR Mn) 34.5% 12.0% 21.4% International Domestic 15.3% 5,748 30.9% YoY Growth 22.3% 20.4% margin +103 bps YoY PAT (INR Mn) 41.1% 36.0% 24.0% 41.0% RoW Europe Canada 3,251
Slide 6: Q2FY27 – Other Financial Data Points
Q2FY27 – Other Financial Data Points Debt rose on Mantra earnout and Gennova consolidation payments R&D (INR Mn) Net debt (INR Mn) Net debt to R&D as % of Revenue 3.9% 3.7% 4.2% 3.9% TTM1 0.3 0.6 0.6 0.6 EBITDA (x) 2,014 13,171 10,538 11,026 1,687 1,110 957 4,883 H1FY26 H1FY27 Q2FY26 Q2FY27 31-Mar-2
Slide 7: Q2FY27 – Domestic Business Performance
Q2FY27 – Domestic Business Performance Key Highlights Domestic (INR Mn) ▪ Sustained double-digit YoY growth for the second consecutive quarter, improving from 10% in Q1FY27 to 12% in Q2FY27 22,506 ▪ Growth led by women’s health, cardio-metabolics and CNS visible in Q2FY27 20,261 IQVIA1 growth of key
Slide 8: Q2FY27 – International Business Performance
Q2FY27 – International Business Performance Europe (INR Mn) Canada (INR Mn) RoW (INR Mn) 11,410 8,578 11,515 34.6% 24.3% 8,479 6,900 42.8% 8,064 6,043 4,312 6,297 4,444 36.0% 3,476 24.0% 4,463 41.1% H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 ▪ Strong delivery
Slide 9: P&L Summary | Q2FY27
P&L Summary | Q2FY27 INR Mn except % Q2FY27 Q2FY26 YoY % Q1FY27 QoQ % H1FY27 H1FY26 YoY % Revenue from Operations 28,205 22,698 24.3% 25,804 9.3% 54,009 43,704 23.6% Domestic 11,553 10,314 12.0% 10,953 5.5% 22,506 20,261 11.1% International 16,652 12,383 34.5% 14,851 12.1% 31,503 23,443 34.5% RoW 6,
Slide 10: Balance Sheet Summary
Balance Sheet Summary Equity & Liabilities (INR Mn) Sep 30, 2026 Mar 31, 2026 Assets (INR Mn) Sep 30, 2026 Mar 31, 2026 Shareholder’s Funds 53,439 49,500 Non-Current Assets 38,153 40,004 Share Capital 1,897 1,896 PP&E, CWIP and ROU assets 26,348 24,908 Reserves & Surplus 51,542 47,604 Goodwill 4,278
Slide 11: Cash Flow Summary
Cash Flow Summary Particulars (INR Mn) H1 FY27 H1 FY26 Profit before tax 8,394 6,322 Depreciation and amortisation 2,192 2,041 Finance cost 671 593 Corporate Tax / Advance tax (net of refund) (2,887) (1,838) (Increase) / decrease in Net working Capital (1,192) (4,253) Others 57 (302) Net cash from o
Slide 12: For further information
For further information Institutional investors and analysts can contact: Saurabh Paliwal Investor.Relations@emcure.com Q2FY27 Conference Call Details Date: Tuesday, 3rd November 2026 Time: 04:00 pm IST To Register: Click Here Registered Office Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., H
Emcure Pharmaceuticals — Q2 FY27 Earnings Presentation on 6ix